Vascular Biogenics (VBLT) Issues Quarterly Earnings Results

Vascular Biogenics (NASDAQ:VBLT) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.06), MarketWatch Earnings reports. The firm had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $2.30 million. Vascular Biogenics had a negative return on equity of 30.67% and a negative net margin of 2,724.02%.

NASDAQ:VBLT opened at $1.30 on Friday. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.01. The stock has a market cap of $43.42 million, a price-to-earnings ratio of -2.10 and a beta of -0.25. Vascular Biogenics has a 52 week low of $0.60 and a 52 week high of $3.10.

A number of equities analysts recently commented on the company. Zacks Investment Research raised Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Saturday, March 30th. Chardan Capital reaffirmed a “hold” rating and issued a $3.00 target price on shares of Vascular Biogenics in a report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Vascular Biogenics in a report on Thursday. Finally, ValuEngine cut Vascular Biogenics from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st.



Several hedge funds have recently modified their holdings of VBLT. RBF Capital LLC bought a new stake in shares of Vascular Biogenics in the fourth quarter worth about $353,000. First Republic Investment Management Inc. increased its holdings in shares of Vascular Biogenics by 7.4% in the first quarter. First Republic Investment Management Inc. now owns 145,000 shares of the biopharmaceutical company’s stock worth $220,000 after purchasing an additional 10,000 shares during the last quarter. Menta Capital LLC bought a new stake in shares of Vascular Biogenics in the first quarter worth about $35,000. Athena Capital Advisors LLC bought a new stake in shares of Vascular Biogenics in the first quarter worth about $25,000. Finally, Acadian Asset Management LLC increased its holdings in shares of Vascular Biogenics by 272.3% in the first quarter. Acadian Asset Management LLC now owns 59,427 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 43,466 shares during the last quarter. 14.06% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Vascular Biogenics (VBLT) Issues Quarterly Earnings Results” was originally posted by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://dakotafinancialnews.com/2019/05/17/vascular-biogenics-vblt-issues-quarterly-earnings-results.html.

About Vascular Biogenics

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Further Reading: How do analysts define an oversold condition?

Earnings History for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.